marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-14-2024
Outlook Therapeutics Balance Sheet 2011-2024 | OTLK
Annual Balance Sheet Outlook Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-17.4 M | -14.4 M | -7.97 M | 3.37 M | 16.2 M | 14.9 M | 5.08 M | 12.8 M | 12.9 M | - | - | - | |
Long Term Debt |
- | 4.27 K | 16 K | 904 K | 50.3 K | 98.5 K | 13.4 M | 2.23 M | 3.65 M | 4.92 M | - | - | - |
Long Term Debt Current |
- | 27 K | 42.9 K | 187 K | 1.03 M | 66.5 K | 52.6 K | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 1.02 M | 7.61 M | 11.1 M | 22.7 M | 8.47 M | 14.9 M | 27.2 M | - | - | - |
Total Current Liabilities |
46.7 M | 19.7 M | 6.75 M | 15.9 M | 20.3 M | 32 M | 28.7 M | 20.4 M | - | - | - | - | - |
Total Liabilities |
46.7 M | 19.8 M | 18.2 M | 16.9 M | 27.9 M | 43.1 M | 51.5 M | 28.9 M | 35.2 M | 64.3 M | - | - | - |
Deferred Revenue |
- | - | - | - | - | 1.74 M | 3.09 M | 1.21 M | 1.5 M | 1.98 M | - | - | - |
Retained Earnings |
-468 M | -409 M | -343 M | -290 M | -254 M | -216 M | -186 M | -147 M | -45.2 M | -94.1 M | - | - | - |
Total Assets |
32.3 M | 28.5 M | 22.8 M | 19.7 M | 17.1 M | 22.3 M | 20.7 M | 23.7 M | 11.6 M | 35 M | - | - | - |
Cash and Cash Equivalents |
23.4 M | 17.4 M | 14.5 M | 12.5 M | 8.02 M | 1.72 M | 3.19 M | 2.35 M | 9.07 M | - | - | - | - |
Book Value |
-14.4 M | 8.74 M | 4.61 M | 2.83 M | -10.8 M | -20.8 M | -30.7 M | -5.2 M | -23.5 M | -29.3 M | - | - | - |
Total Shareholders Equity |
-14.4 M | 8.74 M | 4.61 M | 2.83 M | -16.1 M | -25.5 M | -33.7 M | -5.2 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Outlook Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
260 K | - | - | - | - | - | 1.08 K | 4.27 K | 7.35 K | 10.3 K | 13.2 K | 16 K | 21.7 K | 16 K | 35.7 K | 42.5 K | 545 M | 3.6 M | 3.6 M | 50.3 M | 62.9 K | 75.1 K | 86.9 K | 98.5 K | 98.5 K | 98.5 K | 143 K | 151 K | 151 K | 151 K | 191 K | 2.23 M | 2.23 M | 2.23 M | - | 2.92 M | 2.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
131 M | 193 M | 46 M | 46.7 M | 50 M | 43.5 M | 46.9 M | 19.8 M | 18.5 M | 31.7 M | 29.9 M | 18.2 M | 20.1 M | 18.2 M | 23 M | 16.9 M | 16.9 M | 16.9 M | 35.8 M | 27.9 M | 27.9 M | 27.9 M | 40.2 M | 43.1 M | 43.1 M | 43.1 M | 40.2 M | 51.5 M | 51.5 M | 51.5 M | 42.3 M | 30.6 M | 28.9 M | 28.9 M | - | 62.6 M | 62.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.34 M | 2.34 M | 2.39 M | 1.74 M | 1.74 M | 1.74 M | 2.75 M | 3.09 M | 3.09 M | 3.09 M | 1.21 M | 1.21 M | 1.21 M | 1.21 M | - | 1.98 M | 1.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-549 M | -593 M | -479 M | -468 M | -455 M | -434 M | -428 M | -409 M | -395 M | -377 M | -357 M | -343 M | -329 M | -343 M | -304 M | -290 M | -290 M | -290 M | -271 M | -254 M | -254 M | -254 M | -230 M | -216 M | -216 M | -216 M | -188 M | -186 M | -186 M | -186 M | -166 M | -147 M | -147 M | -147 M | - | -94.1 M | -94.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
47.1 M | 59 M | 21.7 M | 32.3 M | 44.4 M | 54 M | 62.7 M | 28.5 M | 38.6 M | 67.7 M | 78.7 M | 22.8 M | 32.9 M | 22.8 M | 12.5 M | 19.7 M | 19.7 M | 19.7 M | 10.4 M | 17.1 M | 17.1 M | 17.1 M | 18.7 M | 22.3 M | 22.3 M | 22.3 M | 32.3 M | 20.7 M | 20.7 M | 20.7 M | 20.4 M | 25.4 M | 23.7 M | 23.7 M | - | 35 M | 35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
32 M | 47.2 M | 10.4 M | 23.4 M | 33.7 M | 43.6 M | 52.3 M | 17.4 M | 26 M | 58.4 M | 70.2 M | 14.5 M | 19.7 M | 14.5 M | 5.57 M | 12.5 M | 12.5 M | 12.5 M | 1.33 M | 8.02 M | 8.02 M | 8.02 M | 228 K | 1.72 M | 1.72 M | 1.72 M | 13.8 M | 3.19 M | 3.19 M | 13.8 M | 2.08 M | 2.35 M | 2.35 M | 2.08 M | 5.58 M | 9.07 M | 9.07 M | 426 K | - | 2.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-83.7 M | -134 M | -24.3 M | -14.4 M | -5.5 M | 10.5 M | 15.8 M | 8.74 M | 20.1 M | 36 M | 48.8 M | 4.61 M | 12.7 M | 4.61 M | -10.5 M | 2.83 M | 2.83 M | 2.83 M | -25.4 M | -10.8 M | -10.8 M | -10.8 M | -21.5 M | -20.8 M | -20.8 M | -20.8 M | -7.9 M | -30.7 M | -30.7 M | -30.7 M | -21.8 M | -5.17 M | -5.2 M | -5.2 M | - | -27.6 M | -27.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-83.7 M | -134 M | -24.3 M | -14.4 M | -5.5 M | 10.5 M | 15.8 M | 8.74 M | 20.1 M | 36 M | 48.8 M | 4.61 M | 12.7 M | 20.7 M | -10.5 M | 2.83 M | -10.5 M | -10.5 M | -30.9 M | -16.1 M | -16.1 M | -30.9 M | -26.4 M | -25.5 M | -25.5 M | -25.5 M | -25.1 M | -33.7 M | -33.7 M | -33.7 M | -21.8 M | -5.17 M | -5.2 M | -5.2 M | - | -54.2 M | -54.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency